Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma.
Biomarkers, Tumor
/ metabolism
DNA Mutational Analysis
Delphi Technique
Humans
Interleukin-10
/ metabolism
Interleukin-6
/ metabolism
Intraocular Lymphoma
/ diagnosis
Lymphoma, Large B-Cell, Diffuse
/ diagnosis
Mutation, Missense
Myeloid Differentiation Factor 88
/ genetics
Retinal Neoplasms
/ diagnosis
Retrospective Studies
Surveys and Questionnaires
Vitreous Body
/ metabolism
Vitreoretinal lymphoma
consensus recommendations
diagnosis
Journal
Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169
Informations de publication
Date de publication:
03 Apr 2021
03 Apr 2021
Historique:
pubmed:
20
5
2021
medline:
22
1
2022
entrez:
19
5
2021
Statut:
ppublish
Résumé
To provide recommendations for diagnosis of vitreoretinal lymphoma (VRL). Literature was reviewed for reports supporting the diagnosis of VRL. A questionnaire (Delphi 1 round) was distributed to 28 participants. In the second round (Delphi 2), items of the questionnaire not reaching consensus (75% agreement) were discussed to finalize the recommendations. Presenting symptoms include floaters and painless loss of vision, vitreous cells organized into sheets or clumps. Retinal lesions are usually multifocal creamy/white in the outer retina. Other findings include retinal lesions with "leopard-skin" appearance and retinal pigment epithelium atrophy. Severe vitreous infiltration without macular edema is the most likely presentation. Diagnostic vitrectomy should be performed. Systemic corticosteroid should be discontinued at least 2 weeks before surgery. An interleukin (IL)-10:IL-6 ratio > 1, positive mutation for the myeloid differentiation primary response 88 gene and monoclonality are indicators of VRL. Multi-modal imaging (optical coherence tomography, fundus autofluorescence) are recommended. A consensus meeting allowed the establishment of recommendations important for the diagnosis of VRL.
Identifiants
pubmed: 34009095
doi: 10.1080/09273948.2021.1878233
doi:
Substances chimiques
Biomarkers, Tumor
0
IL10 protein, human
0
IL6 protein, human
0
Interleukin-6
0
MYD88 protein, human
0
Myeloid Differentiation Factor 88
0
Interleukin-10
130068-27-8
Types de publication
Consensus Development Conference
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM